Arcus Biosciences, a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, will host a conference call and webcast on Wednesday, August 5, 2026. The management team will discuss the company's financial results and pipeline updates for the quarter ended June 30, 2026, at 1:30 PM PT / 4:30 PM ET.

Conference Call Details

Investors can listen to the conference call by dialing +1 (585) 542-9983 (local) or +1 (833) 461-5787 (toll-free), using Meeting ID: 156828313. Online registration is also available through the provided link. The live webcast and accompanying slide presentation will be accessible in the "Investors & Media" section of the Arcus Biosciences website. A replay of the webcast will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. The company is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways. Its investigational medicines include casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer.

HC Wainwright analyst Emily Bodnar has maintained a Buy rating on Arcus Biosciences and raised the price target to $45 from $32. The revised target reflects increased confidence in the company's prospects following the analyst's review of its aggressive push into first-line clear cell renal cell carcinoma (ccRCC) development.

Rating and Target Details

The firm's decision to upgrade the price target underscores a positive outlook on Arcus Biosciences' performance. The previous target of $32 has been adjusted upward by $13 to the new level of $45.

Casdatifan Development Strategy

Arcus Biosciences is aggressively executing a holistic strategy to embed casdatifan into the treatment paradigm. This includes combinations with the most commonly used regimen in the first-line setting, anti-PD-1 plus anti-CTLA-4. The company is enrolling a cohort in the Phase 1/1b ARC-20 study to generate the dataset that will support the initiation of the corresponding Phase 3 study at year-end 2026.

Revenue Projections and Market Outlook

The updated price target includes casdatifan revenues for the broad first-line ccRCC opportunity, in addition to previously modeled revenues in first-line post-immuno-oncology (IO) patients and second-line post-IO patients. Analyst Bodnar assumes around $2.2 billion in peak global unadjusted revenues for first-line, and continues to assume approximately $2 billion in peak global unadjusted revenues for the post-IO setting.

Differentiation and Risk Assessment

HC Wainwright assumes a lower probability of success (POS) of 30% for first-line ccRCC given the program is early in development with less clinical evidence. This follows the LITESPARK-012 trial of Merck & Co Inc.'s Keytruda plus Lenvima plus Welireg combo failing to meet its primary endpoint. Despite the risk, Bodnar believes casdatifan is differentiated from Merck's Welireg (belzutifan) with much greater potency and PD effect, which has contributed to potentially best-in-class efficacy in later-line settings.

Arcus Biosciences is listed on the NYSE under the ticker symbol RCUS.